LungLife AI (LLAI) Share Price, News & Analysis

Company Overview

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

Key Stats

• Today's Range: 2.25 to 3
• 50-Day Range: 0.80 to 2.65
• 52-Week Range: 0.80 to 27
• Volume: 895,013 shs
• Average Volume: 437,003 shs
• Market Capitalization: £971,981.08
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LLAI Stock Analysis - Frequently Asked Questions

How have LLAI shares performed this year?

LungLife AI's stock was trading at GBX 8.50 at the beginning of 2025. Since then, LLAI shares have decreased by 65.5% and is now trading at GBX 2.93.
View the best growth stocks for 2025 here.

How do I buy shares of LungLife AI?

Shares of LLAI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:LLAI
• CIK: N/A
• Web: lunglifeai.com
• Phone: 805 409 9868
• Fax: N/A
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (12.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,217,306.35
• Net Margins: -15,403.45%
• Pretax Margin: N/A
• Return on Equity: -56.38%
• Return on Assets: -27.28%

Debt

• Debt-to-Equity Ratio: 2.66
• Current Ratio: 2.83
• Quick Ratio: 9.85

Sales & Book Value

• Annual Sales: £33,871.03
• Price / Sales: 27.10
• Cash Flow: GBX 1.22 per share
• Price / Cash Flow: 2.28
• Book Value: GBX 27.96 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 33,139,484
• Free Float: N/A
• Market Cap: £917,963.72
• Optionable: Not Optionable
• Beta: -0.30